# US 2006/0188981 A1 · MN gene and protein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0188981 A1
- Document ID: US20060188981A1
- Status: Published application
- Kind: A1
- Application number: 11/356,568
- Filed: 2006-02-17
- Published: 2006-08-24
- Earliest claimed: 2001-12-13
- Assignees: Institute of Virology of the Slovak Academy of Sciences
- Inventors: Adrian Harris; Peter Ratcliffe
- Web page: https://patentgrep.com/patent/US20060188981A1

## CPC

- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- G01N 2333/988: Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Identified herein is the location of the MN protein binding site, and MN proteins/polypeptides that compete for attachment to vertebrate cells with immobilized MN protein. Such MN proteins/polypeptides prevent cell-cell adhesion and the formation of intercellular contacts. The MN protein binding site is a therapeutic target that can be blocked by organic or inorganic molecules, preferably organic molecules, more preferably proteins/polypeptides that specifically bind to that site. Therapeutic methods for inhibiting the growth of preneoplastic/neoplastic vertebrate cells that abnormally express MN protein are disclosed. Vectors are provided that encode the variable domains of MN-specific antibodies and a flexible linker polypeptide separating those domains. Further vectors are disclosed that encode a cytotoxic protein/polypeptide operatively linked to the MN gene promoter or a MN gene promoter fragment comprising the HIF-1 consensus binding sequence, and which vectors preferably further encode a cytokine. The MN gene promoter is characterized, and the binding site for a repressor of MN transcription is disclosed. Further, the hypoxia inducibility of the MN gene and the uses of such induciblity inducibility are disclosed.

## Claims

### Claim at position 1

1-11. (canceled)

### Claim 12

A method which is diagnostic/prognostic for a preneoplastic/neoplastic disease afflicting a subject vertebrate, comprising detecting hypoxia in a sample comprising preneoplastic/neoplastic tissue taken from said vertebrate, which tissue normally expresses no or low MN/CA IX protein, said detecting comprising:
a) detecting MN/CA9 gene expression product in said vertebrate tissue;
b) determining if said MN/CA9 gene expression product levels are abnormally high; and
c) concluding that the presence of MN/CA9 gene expression product at abnormally high levels indicates the presence of hypoxia in said vertebrate tissue, or that the absence or low levels of said MN/CA9 gene expression product indicates the absence of hypoxia in said vertebrate tissue.

### Claim 13 (depends on 12)

The method of claim 12 wherein said hypoxia is chronic hypoxia.

### Claim 14 (depends on 12)

The method of claim 12 wherein said hypoxia represents a tissue oxygen tension of about 1% or less.

### Claim 15 (depends on 12)

The method of claim 12 wherein the presence or level of hypoxia in said tissue is considered indicative of a poorer prognosis.

### Claim 16 (depends on 15)

The method of claim 15, wherein a poorer prognosis is measured in terms of shortened survival or increased risk of recurrence of said preneoplastic/neoplastic disease.

### Claim 17 (depends on 12)

The method of claim 12 wherein said method is used as an aid in making a therapeutic decision in the treatment of said preneoplastic/neoplastic disease afflicting said vertebrate.

### Claim 18 (depends on 17)

The method of claim 17 wherein said method comprises predicting patient response to a specific therapy or specific therapies.

### Claim 19 (depends on 17)

The method of claim 17 wherein said therapeutic decision comprises a decision to treat said disease with a hypoxia-modifying therapy if hypoxia is present or present in high levels.

### Claim 20 (depends on 17)

The method of claim 17 wherein said therapeutic decision comprises a decision to treat said disease with bio-reductive drugs if hypoxia is present or present in high levels.

### Claim 21 (depends on 17)

The method of claim 17 wherein said therapeutic decision comprises a decision to treat said disease with radiation and/or chemotherapy if hypoxia is absent or present in low levels.

### Claim 22 (depends on 17)

The method of claim 17, wherein said therapeutic decision comprises a decision to treat said disease with a combination of radiotherapy and hypoxia-directed therapy if hypoxia is present.

### Claim 23 (depends on 17)

The method of claim 17 wherein said therapeutic decision comprises a decision to treat said disease more aggressively if hypoxia is present in said tissue, or less aggressively if hypoxia is absent in said tissue.

### Claim 24 (depends on 12)

The method of claim 12, wherein said disease is selected from the group consisting of preneoplastic/neoplastic diseases related to head and neck cancers, head and neck squamous cell carcinoma, uterine carcinoma, uterine cervical carcinoma, renal cancer, breast cancer, lung cancer, pancreatic cancer, soft tissue sarcoma, bladder cancer, colorectal cancer, esophageal cancer, prostate cancer, ovarian cancer, endometrial cancer, squamous cell and adenosquamous carcinomas, mesodermal tumors, neuroblastomas, retinoblastomas, sarcomas, osteosarcomas, Ewing's sarcoma, melanomas, vaginal cancer, vulval cancer, gastrointestinal cancer, urinary tract cancer, kidney cancer, non-small cell lung cancer, skin cancer, liver cancer, cervical squamous cell carcinoma, cervical adenosquamous carcinoma, cervical adenocarcinoma, cervical metaplasia, and condyloma.

### Claim 25 (depends on 12)

The method of claim 12, wherein said preneoplastic/neoplastic sample is a formalin-fixed, paraffin-embedded tissue sample.

### Claim 26 (depends on 12)

The method of claim 12, wherein said MN/CA9 gene expression product comprises an MN/CA IX protein or MN/CA IX polypeptide.

### Claim 27 (depends on 12)

The method of claim 12, wherein said MN/CA9 gene expression product comprises an mRNA encoding an MN/CA IX protein or MN/CA IX polypeptide, or a cDNA complementary to said mRNA.

### Claim 28 (depends on 12)

The method according to claim 12, wherein said detecting step (a) comprises the use of an assay selected from the group consisting of Western blots, enzyme-linked immunosorbent assays, radioimmunoassay, competition immunoassays, dual antibody sandwich assays, immunohistochemical staining assays, agglutination assays, and fluorescent immunoassays.

### Claim 29 (depends on 12)

The method of claim 12, wherein said detecting step (a) is by PCR, RT-PCR, real-time PCR, or by quantitative real-time RT-PCR.

### Claim 30 (depends on 12)

The method according to claim 12, wherein said detecting step (a) comprises the use of the monoclonal antibody secreted by the hybridoma VU-M75 which has Accession No. ATCC HB 11128.

### Claim 31 (depends on 12)

The method of claim 12, wherein said vertebrate is a mammal.

### Claim 32 (depends on 31)

The method of claim 31, wherein said mammal is a human.

### Claim 33

A method for determining the percentage of the cells in a vertebrate tumor that are hypoxic, comprising quantifying MN/CA9 gene expression product in a tissue sample taken from said tumor.

### Claim 34

A method for determining the relative degree of hypoxia in a tissue in a vertebrate, comprising:
a) detecting MN/CA9 gene expression product in said tissue; and
b) quantifying said MN/CA9 gene expression product, wherein the relative level of MN/CA9 gene expression product indicates the relative degree of hypoxia.
